Group 1 - The company, Harbin Yuyuantang Traditional Chinese Medicine Clinic Group Co., Ltd., is accelerating its IPO process on the Hong Kong Stock Exchange, having appointed Tiger Brokers as a co-ordinator and submitted its listing application [1][19] - Founded in 2015, the company started as a small clinic and has expanded its operations significantly, now owning 48 licensed medical institutions across several provinces [2][21] - The company has achieved a high customer retention rate of 81.1% and has seen a substantial increase in new customers, growing from approximately 9,950 in 2023 to about 30,900 in 2024 [7][23] Group 2 - The financial performance of the company has shown significant growth, with revenues of 150 million yuan in 2023 and projected revenues of 215 million yuan in 2024, reaching 284 million yuan in the first nine months of 2025 [10][26] - The company's gross margin is notably high, reported at 56.1% in 2023, increasing to 62.1% in the first nine months of 2025, which is significantly higher than many competitors in the healthcare sector [11][29] - The traditional Chinese medicine service market in China is expanding, with the market size expected to grow from 659.9 billion yuan in 2019 to approximately 1 trillion yuan in 2024, and projected to reach about 1.62 trillion yuan by 2029 [8][24] Group 3 - The company plans to open 155 to 170 new licensed medical institutions over the next four years, with an estimated capital expenditure of between 233 million yuan and 340 million yuan [14][30] - As of January 6, 2026, the company has 292 full-time medical professionals, including 154 traditional Chinese medicine practitioners, highlighting the challenge of recruiting and retaining qualified staff amid rapid expansion [15][31] - The company faces regulatory challenges, with 33 leased properties not yet completed for fire safety registration, which could impact its IPO process and ongoing compliance [16][32]

Core Viewpoint - The company, Yuyantang, has submitted its prospectus to the Hong Kong Stock Exchange, with Zhuhai International and Guoyuan International acting as joint sponsors, focusing on a "full lifecycle diagnosis and treatment model" based on Traditional Chinese Medicine (TCM) principles [1] Group 1: Business Model - The company operates on a "preventive treatment" philosophy, covering four stages: "pre-disease, desire for disease, existing disease, and post-recovery," providing integrated personalized health solutions that include prevention, adjustment, treatment, and maintenance [1] - Yuyantang employs a strict model of "offline initial diagnosis and online follow-up," ensuring all patients complete diagnostic assessments at licensed offline institutions, while the online platform manages follow-ups, chronic disease care, and health management to ensure service continuity [1] Group 2: Market Position - According to a Frost & Sullivan report, Yuyantang ranks as the second-largest private chain TCM healthcare service provider in Northern China by total revenue from TCM outpatient services and clinics as of 2024, and it ranks first in revenue from medicinal pastes [1] - The company boasts the highest customer repurchase rate among private chain TCM healthcare service providers, achieving a repurchase rate of 81.1% for the nine months ending September 30, 2025 [1] Group 3: Infrastructure and Expertise - Yuyantang has established a network of 48 self-built and operated licensed medical institutions in Northern China, all managed through a unified cloud-based healthcare information system (HIS) for digital management [1] - The company offers personalized TCM prescriptions, including decoctions, pills, powders, and pastes, and possesses proprietary non-heritage pastes and several in-house developed formulations as protected therapeutic assets [1] - Yuyantang employs 292 full-time medical professionals, with a research committee comprising 98 experts, integrating knowledge from both internal medical teams and external research collaborators [1]